Early Success With New Target in Atopic Dermatitis

(MedPage Today) -- NEW YORK CITY--An oral drug that targets Th2 activity in atopic dermatitis reduced disease activity by as much as 50% after 6 weeks, results of a small placebo-controlled study showed.
At 4 weeks of treatment with RPT193...